Dialyzability of faropenem sodium during hemodialysis in patients with chronic renal failure

Dialyzability of faropenem sodium during hemodialysis in patients with chronic renal failure - Dialyzability of faropenem sodium during hemodialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019365

Enrollment

Registered

2015-10-17

Start date

2006-12-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure, infection

Interventions

To measure the concentration of faropenem, blood samples were collected from both the pre- and post-dialyzer lines before, and at 2 and 4 hr after hemodialysis.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Hemodialysis has been carried out due to chronic renal failure 2. Hemodialysis was carried out continuously for more than one month 3. Faropenem is adapted

Exclusion criteria

Exclusion criteria: 1. Patients with poorly controlled diabetes (HbA1c 7.0% or more) 2. Patients with hepatic failure 3. Patients have a history of allergy to beta-lactam antibiotics 4. Patients have been taking faropenem within one week 5. Patients taking sodium valproate 6. Patients taking warfarin 7. Pregnant women and nursing woman 8. Judged inappropriate to participate in this study by a doctor

Design outcomes

Primary

Measure	Time frame
Hemodialysis clearance of faropenem	—

Countries

Japan

Contacts

Public ContactKentaro Ushijima

Jichi Medical University Division of Clinical Pharmacology, Department of Pharmacology

ushijima-kentarou@umin.ac.jp0285-58-7388

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026